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A Genetically Modified Adenoviral Vector with a Phage
Display-Derived Peptide Incorporated into Fiber Fibritin
Chimera Prolongs Survival in Experimental Glioma
Julius W. Kim,1 J. Robert Kane,1 Jacob S. Young,1 Alan L. Chang,1 Deepak Kanojia,1
Ramin A. Morshed,1 Jason Miska,1 Atique U. Ahmed,1 Irina V. Balyasnikova,1
Yu Han,1 Lingjiao Zhang,1 David T. Curiel,2 and Maciej S. Lesniak1,*
1Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois; 2Cancer Biology Division, Biologic Therapeutics Center,
Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.
The dismal clinical context of advanced-grade glioma demands the development of novel therapeutic
strategies with direct patient impact. Adenovirus-mediated virotherapy represents a potentially effective
approach for glioma therapy. In this research, we generated a novel glioma-specific adenovirus by insti-
tuting more advanced genetic modifications that can maximize the efficiency and safety of therapeutic
adenoviral vectors. In this regard, a glioma-specific targeted fiber was developed through the incorpora-
tion of previously published glioma-specific, phage-panned peptide (VWT peptide) on a fiber fibritin-based
chimeric fiber, designated as ‘‘GliomaFF.’’ We showed that the entry of this virus was highly restricted to
glioma cells, supporting the specificity imparted by the phage-panned peptide. In addition, the stability of
the targeting moiety presented by fiber fibritin structure permitted greatly enhanced infectivity. Fur-
thermore, the replication of this virus was restricted in glioma cells by controlling expression of the E1
gene under the activity of the tumor-specific survivin promoter. Using this approach, we were able to
explore the combinatorial efficacy of various adenoviral modifications that could amplify the specificity,
infectivity, and exclusive replication of this therapeutic adenovirus in glioma. Finally, virotherapy with
this modified virus resulted in up to 70% extended survival in an in vivomurine glioma model. These data
demonstrate that this novel adenoviral vector is a safe and efficient treatment for this difficult malig-
nancy.
INTRODUCTION
The heterogeneous tumor milieu and highly
aggressive nature of glioblastoma (GBM) makes
therapeutic treatments especially difficult. As a
result, the prognosis for patients with this tumor
entity is a mere 14.6 months even after a combi-
nation of surgery, radiotherapy, and temozolomide
chemotherapy.1 This unfortunate situation does
not offer much hope and is precisely why such a
complicated condition requires advanced, specified
treatment options heretofore unavailable.
Because of the flexibilities permitted for genetic
modification and the well-characterized biology
of adenovirus, the human adenovirus serotype 5
(HAd5) is applicable in promising cancer therapies
as an oncolytic agent, itself, or as a cytotoxic gene(s)
carrier.2–4 Despite this, glioma cells are highly
variable and express little to no coxsackievirus and
adenovirus receptor (CAR), the primary receptor of
HAd5.3 This makes it difficult to use HAd5 in a
virotherapeutic approach to glioma. For this rea-
son, most of the current adenoviral vectors for
glioma virotherapies are genetically modified to
enhance their infectivity in glioma cells. These
infectivity-enhanced HAd5 vectors cannot, how-
ever, distinguish between neoplastic and normal
cells, which results in nonspecific viral infection
and the death of peripheral, nonneoplastic cells as
an unfortunate side effect.5
To overcome this current hurdle of adenovirus-
mediated virotherapy against glioma, we applied
new genetic modifications to the tropism-dictating
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fiber to engineer a virus that selectively and effi-
ciently infects, and thereby lyses, glioma cells. Al-
though there are several targetable glioma-specific
proteins such as EGFRvIII, IL13Ra2, and CD133,
the levels of their expression are highly variable
in heterogeneous glioma cells.6,7 For this reason,
we selected a previously published glioma-specific
binding peptide, VTW peptide, originating from
the phage biopanning technique.8 This tech-
nique has shown its effectiveness for selecting
small peptide(s) that recognize a specific cell or a
tissue type.9,10 It is a particularly suitable alter-
native when no clear targetable motif is known to
be related to the heterogeneity of the tumor cell
population.
Genetic modifications of the HAd5 fiber have
typically been accomplished by adding targeting
peptides to the C terminus of the fiber or by re-
placing CAR-binding residues on the fiber knob
domain with targeting peptides, which limits the
size of incorporable peptides (maximum of 10–15
amino acids) and may cause instability of the fiber
because of the charge associated with incorporated
peptides.11 Therefore, to increase the stability and
number of targeting peptides, we replaced the en-
tire wild-type fiber with the T4 bacteriophage-
oriented fibritin trimerization domain.12 This
approach is especially stable and particularly ef-
fective in the matter of incorporating a large tar-
geting motif such as CD40L or a single-chain
antibody without affecting the binding ability of
the original targeting moiety, enhancing both the
infectivity and specificity of a newly engineered
virus.13–15
To restrict the adenoviral replication to occur
only in neoplastic cells, several approaches were
developed including transcriptionally regulating
the expression of the replication-essential gene,
early gene 1 (E1), under the control of tumor-
specific promoters (TSPs; e.g., survivin, midkine,
and CXCR4)16,17 and using unique cancer molecu-
lar characteristics: interaction between the E1 vi-
ral protein with Rb in neoplastic cells (the so-called
E1D24 approach).1 We have previously shown that
the survivin promoter is highly active in glioma
cells yet minimally active to inactive in normal
cells.16 Therefore, to further minimize any cyto-
pathic effects mediated by virus replication in
normal cells, the replication of this new glioma-
targeted adenovirus was regulated by controlling
the expression of the E1 gene by means of the
survivin promoter. In this research, we explored
the efficacy of advanced novel adenoviral genetic
modifications to augment the specificity, infectiv-
ity, and exclusive replication in glioma in a way
that could achieve promising therapeutic results in
human clinical applications.
MATERIALS AND METHODS
Cell lines
Human embryonic kidney (HEK) 293, HEK 293-
F28 stably expressing Ad5 wild-type fibers, Chi-
nese hamster ovary (CHO) cells, CHO-hCAR cells
stably expressing human CAR, two glioma cell
lines (U87 and U251), two nonneoplastic cell lines
(NHA [normal human astrocytes] and NSC [neu-
ronal stem cells, HB1.F3 CD]), and two neoplas-
tic cell lines of other originated anatomical sites
(A549 [human lung carcinoma cell line] and MDA-
MB231-BrM2 [brain metastatic breast cancer cell
line; a gift from J. Massague´]) were cultured in
medium containing 10% fetal bovine serum (FBS;
Hyclone, Logan, UT), penicillin (100U/ml), and
streptomycin (100mg/ml) (Mediatech, Herndon,
VA) and incubated at 37C in 5% CO2 under hu-
midified conditions. U87-luc was generated by
transfecting pGL4 encoding firefly luciferase with
Lipofectamine 2000 according to the manufactur-
er’s instructions (Invitrogen, Carlsbad, CA) and
cultured in the same way as described previously.
Primary human brain tumor specimen (GBM43
and GBM6) were obtained from D. James (UCSF,
San Francisco, CA) in accordance with a proto-
col approved by the institutional review board at
UCSF. The establishment and maintenance via
implantation on the flank side of nude mice was
previously described.18
Genetic modifications and virus production
To generate a fiber shuttle vector, pKan 566
carrying the gene encoding fiber fibritin was
used.15 The nucleotide sequence for the selected
glioma cell-binding peptide, VTWTPQAWFQWV,
was inserted at the C terminus of fiber fibritin by a
standard molecular technique, resulting in pKan-
GliomaFF. With this fiber shuttle vector, two re-
combinant HAd5 backbones containing either an
enhanced green fluorescent protein (eGFP) under
the control of the cytomegalovirus (CMV) promoter
in the E1-deleted region (replication-incompetent
Ad5GliomaFF-CMV-GFP) or the E1 gene under
the control of the survivin promoter (condition-
ally replicating Ad5GliomaFF-Sur E1) were con-
structed. The recombinant viruses were rescued
and propagated in HEK293-F28 until the last
propagation step, and then the last propagation in
20· 175 flasks was done in HEK293 cells. Viruses
were purified by two rounds of CsCl gradient ul-
tracentrifugation and their titer was determined
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at 260nm.19 The viral titer of Ad5GliomaFF was
highly equivalent to that of Ad5WT (Supplemen-
tary Fig. S3; supplementary data are available
online at www.liebertpub.com/hum).
Western blot
Purified adenoviral particles (1 ·1010) were di-
luted in Laemmli buffer, incubated either at room
temperature (unboiled samples) or at 95C (boiled
samples) for 10min, and loaded to a 7.5% sodium
dodecyl sulfate (SDS)–polyacrylamide gel (Bio-Rad,
Hercules, CA). After electrophoretic separation,
samples were transferred onto a polyvinylidene
difluoride (PVDF) membrane and detected with a
4D2 monoclonal anti-fiber tail antibody (diluted
1:3000) (Thermo Scientific, Rockford, IL) followed
by horseradish peroxidase (HRP)-tagged anti-mouse
IgG secondary antibody (diluted 1:5000) (Santa Cruz
Biotechnology, Santa Cruz, CA).
Virus infectivity analysis
Cells (3 ·105) were plated in 24-well plates
and incubated overnight. Each virus sample was
diluted to a multiplicity of infection (MOI) of 300
viral particles (VP)/cell in 500ll of infection me-
dium containing 2% FBS in Dulbecco’s modified
Eagle’s medium (DMEM). The cells were infected
with each virus for 2 hr at 37C. Virus-containing
medium was replaced with fresh medium contain-
ing 2% FBS and cells were maintained at 37C at
atmospheric humidity and 5% CO2 for 3 days until
flow cytometric analysis. For the VTW peptide in-
hibition assay, cells were incubated with 0–100 lg
of the VTW peptide (Peptide 2.0, Chantilly, VA) for
1 hr at 37C before viral infection.
Oncolytic efficacy
MTT assay. Viral infection was done in the
same way as described previously except that an
MOI of 100VP/cell was used. The MTT assay was
performed with cell proliferation kit I (MTT) ac-
cording to the manufacturer’s instruction (Roche,
Mannheim, Germany).
Crystal violet staining. Cell were infected with
serially diluted MOIs (0–100VP/cell) and incu-
bated for 8 days at 37C at atmospheric humidity
containing 5% CO2. After fixing with 4% parafor-
maldehyde, cells were stained with 500ll of 0.1%
crystal violet solution in distilled water. After
several washings with water, the plates were dried
completely at room temperature. Crystal violet
staining was dissolved with 500ll of 100% metha-
nol and read with a plate reader at OD570.
Replication efficiency by quantitative
polymerase chain reaction
Viral infection (MOI, 100VP/cell) was done as
described previously. The samples (cells and me-
dium) were collected at 24-, 48-, and 72-hr inter-
vals after viral infection and the DNAs from the
samples were isolated with a DNeasy tissue kit
(Qiagen, Hilden, Germany) according to the man-
ufacturer’s protocol. qPCR was conducted with a
SYBR green qPCR kit (Bio-Rad), using the primers
indicated in Supplementary Table S1. Data anal-
ysis was performed by the 2–DDCT method for rela-
tive quantification, and all sample values were
calculated as a relative ratio to expression values
from Ad5WT.
Animal study
Intracranial glioma xenograft implantation. U87MG-
Luc (2.5 ·105 cells) or GBM43 (1 ·105 cells) glioma
cells were implanted via cranial guide screws as
described previously.18 The mice were anesthe-
tized with a ketamine–xylazine mixture (115/
17mg/kg). A burr hole was made to facilitate ste-
reotactic injection that was performed with a 10-ll
Hamilton syringe (Hamilton, Reno, NV) with a
30-gauge needle. The small-gauge needle was
mounted to a mouse-specific, stereotactic Harvard
apparatus (Harvard Bioscience, Holliston, MA) to
facilitate insertion and was then inserted through
the burr hole to an anatomical position of 3mm in
depth. Male athymic/nude mice were obtained
from Charles River Laboratory (Wilmington, MA)
and were cared for in accordance with a study-
specific animal protocol approved by theUniversity
of Chicago Institutional Animal Care and Use
Committee. Five days after tumor implantation,
mice were randomly separated into two groups and
were then injected with either 10ll of phosphate-
buffered saline (PBS) or 1010 VP in 10ll of PBS.
For in vivo tumor growth analysis, mice were im-
aged for luciferase activity by means of intraperito-
neal injection of d-luciferin (4.5mg/animal, in 150ll
of saline), and bioluminescence analysis was per-
formed 10min after d-luciferin administration by
using a cryogenically cooled, high efficiency, charge-
coupled device camera system (Xenogen, Alame-
da,CA). For survival analysis, animals losing ‡30%
of their body weight or having trouble ambulating,
feeding, or grooming were killed by CO2 adminis-
tration followed by cervical dislocation.
Statistical analysis
All statistical analyses were performed with
GraphPad Prism 4 (GraphPad Software, San
Diego, CA). Sample size for each group was ‡ 3 and
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numerical data were reported as means –SEM.
The Student t test was used for comparisons between
two groups, and analysis of variance (ANOVA)
with Tukey’s post hoc test was used for compari-
sons between more than two groups. Kaplan–
Meier survival curves were generated and the log
rank test was applied to compare survival dis-
tributions. All reported p values were two-sided
and were considered to be statistically significant
at *p <0.05, **p< 0.01, and ***p <0.001.
RESULTS
Generation of glioma-specific
adenoviral vector
Because of the heterogeneity of glioma cells,
there is no known clear surface protein to specifi-
cally target glioma cells.20,21 To achieve specifically
targeted virotherapy against glioma, we applied
novel genetic modifications on the viral tropism
dictating fiber.2We replaced the shaft and the knob
domain of the wild-type fiber with a fiber fibritin
trimerization domain to maximize the stability of
the binding motif12,14,15 and incorporated a phage-
panning-derived glioma-specific VTW peptide8
onto the C terminus of the fiber fibritin domain,
generating a glioma-specific fiber fibritin chimera
(Fig. 1a). To confirm whether the modified fiber
proteins were correctly trimerized and incorpo-
rated into the viral capsids, we performed Western
blot analysis with anti-HAV5-fiber tail (4D2) anti-
body. Two different fiber compositions from non-
heat-denatured samples (trimerized fibers) and
heat-denatured samples (fiber monomers) were
observed at*180 and*60kDa, respectively (Fig.
1b). The trimerization of the chimeric fiber is seen
to be as efficient as that of the wild-type fiber be-
cause the ratio of the two fiber compositions is
relatively equivalent for the two viruses (Fig. 1b).
Thus, these data indicates that the modified fibers,
GliomaFF, are correctly trimerized and incorpo-
rated into HAd5 (Fig. 1b).
Figure 1. Generation and confirmation of the glioma-specific adenovirus. (a) Schematic diagram of a glioma-specific chimera fiber of Ad5GliomaFF. The knob and
the shaft domain of HAd5 fiber were replaced with the fiber fibritin trimerization domain. The glioma-targeted chimeric fiber named GliomaFF was generated by
incorporating the phage-panned glioma-specific peptides (VTW) on the C terminus of the chimeric fiber. (b)Molecular validation of a glioma-specific chimeric fiber of
Ad5GliomaFF: detection of fiber trimerization and incorporation of viral particles byWestern blot analysis with an HAdV-5 tail antibody (4D2). 1· 1010 VP of Ad5CMV-
GFP (lanes 1 and 2) or Ad5GliomFF-CMV-GFP (lanes 3 and 4) in Laemmli buffer was analyzed. Samples, identified as B (boiled, incubation at 95C for 10min) in lanes 2
and 4 andmarked as U (unboiled, incubation at room temperature for 10min) in lanes 1 and 3, show the denaturedmonomeric fiber composition and the nondenatured
trimeric fiber composition, respectively. Makers indicate kilodaltons (kDa). (c) Fluorescence micrograph and (d) flow cytometric analysis of CAR-independent
infection with Ad5GliomaFF-CMV-GFP. Cells were infected with Ad5GliomaFF-CMV-GFP or Ad5CMV-GFP at an MOI of 300 VP/cell for 2 hr on CAR-negative CHO cells
and CAR-positive CHO-hCAR cells, and the virus-containing medium was removed and replaced with fresh medium containing 2% FBS. Fluorescence micrographs
were taken 72 hr postinfection, followed by flow cytometric analysis. All images are representative of three different experiments. Scale bar, 100lm. Each column is
the average of three independent replicates. Means–SEM are plotted. Color images available online at www.liebertpub.com/hum
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CAR-independent infection of Ad5GliomaFF
The deletion of the shaft and knob domains
renders the virus devoid of its natural tropism but
allows for novel targeting specificity by way of the
fiber chimera, considering that the CAR-binding
domain is located on the knob domain. First, to
verify that the fiber modification results in the loss
of CAR-binding ability, we analyzed the infectivity
of the viruses in a human CAR (hCAR)-negative
cell line, the Chinese hamster ovary (CHO) cell
line, and in a CHO-derived cell line, CHO-hCAR,
that stably expresses human CAR. Whereas wild-
type Ad5-CMVGFP showed an approximately 60%
infection rate in the CHO-hCAR cell line compared
with 2% in the CHO cell line, there was no observ-
able change in infection rate with Ad5GliomaFF-
CMVGFP in either cell line (Fig. 1c and d), indicating
that Ad5GliomaFF-CMVGFP infects a cell in a
CAR-independent manner, confirming the loss of
CAR-binding ability.
Glioma-specific and efficient infection
of Ad5GliomaFF
With loss of the CAR-binding ability of Ad5-
GliomaFF, we next investigated whether the glioma-
specific fiber fibritin chimeraheld targeted specificity
by way of fluorescence imaging techniques and flow
cytometric analysis with a panel of glioma cell lines:
Figure 2. Glioma-specific and efficient infection of Ad5GliomaFF. Cells were infected with Ad5GliomaFF-CMV-GFP or Ad5CMV-GFP at an MOI of 300 VP/cell
for 2 hr on glioma cell lines U87 and U251, patient-derived glioma xenograft cell lines GBM43 and GBM6, nonneoplastic cells NHA (normal human astrocytes)
and NSC (neuronal stem cells), and other neoplastic cell lines from various anatomical sites: A549 (human lung adenocarcinoma) and MDA-MB 231-BRM2
(brain metastatic breast cancer). The virus-containing medium was then removed and replaced with fresh medium containing 2% FBS. Fluorescence
micrographs were taken 72 hr postinfection (a and c), followed by flow cytometric analysis (b and d). (e) Viral infection was done in the same way as
described previously except that cells were incubated with VTW peptides for 1 hr before the infection. (f) Infection procedures were done in the same way as
described previously with Ad5GliomaFF-CMV-GFP or Ad5PK7-CMV-GFP, followed by flow cytometric analysis. Scale bar, 100 lm. All images are representative
of three independent experiments. Means– SEM are plotted. Color images available online at www.liebertpub.com/hum
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U87MG, U251MG, GBM43, and GBM6. Whereas
wild-type Ad5-CMV-GPF infected only approxi-
mately 10% of these glioma cell lines on average,
Ad5GliomaFF-CMVGFP infected approximately
70% of these glioma cell lines on average (Fig. 2a
and b).More importantly, this glioma-specific virus
was highly efficient in the infection of cell lines
obtained from patient-derived tumor xenografts:
GBM43 and GBM6 (Fig. 2a and b). These two cell
lines have been shown to be more clinically rele-
vant because they have more intrinsic patient
GBM molecular properties.18 To further confirm
the specificity of the virus, we assessed the infec-
tivity on a panel of nonneoplastic cells: possible by-
stander target cell lines in the brain (NHA [normal
human astrocyte] and NSC [neuronal stem cell]) as
well as other neoplastic cell lines to establish that
this virus is not cancer specific, but glioma specific:
A549 (human lung adenocarcinoma epithelial cell
line) and MDA-MB 231-BRM2 (brain metastatic
breast cancer line). Unlike wild-type Ad5CMV-
GFP, the infectivity of this glioma-specific virus
showed less than 2% on this panel of cell lines (Fig.
2c and d), thereby demonstrating the specificity of
Ad5GliomaFF-CMVGFP. Importantly, minimal in-
fection of possible by-stander target cells (NHA and
NSC) with the glioma-specific virus were observed
(0.13 and 0.17% infection rate, respectively), af-
firming the safety of this virus for glioma vir-
otherapy (Fig. 2c and d). The direct comparison
demonstrated that the infection rate of Ad5-
GliomaFF-CMVGFP on glioma cells is statistically
significant in comparison with that of the viral in-
fection of nonneoplastic, otherwise normal cells
(p < 0.0001) (Supplementary Fig. S1). In addition,
infection with Ad5GliomaFF-CMVGFP is dramat-
ically decreased when the infection was performed
in the present of VTWpeptide, which confirmed the
previously published binding specificity of VTW
peptides (Fig. 2e).22
Whenever a delivery vehicle is designed to target
a specific cell population, there is often a compro-
mise between enhanced specificity and reduced
infection efficacy. Therefore, to verify the infection
efficiency of this glioma-specific virus, we compared
its infectivity with that of the well-established infec-
tivity enhanced glioma virotherapeutic vector
Ad5PK7-CMV-GFP, which infects a cell by binding to
any anionic cell surface proteins through seven lysine
residues (PK7) on the fiber. As shown in Fig. 2f, the
infectivity of this new glioma-specific virus is highly
comparable to that of the infectivity-enhanced virus:
Figure 3. Kinetics of Ad5GliomaFF infectivity. Cells were infected with Ad5GliomaFF-CMV-GFP or Ad5CMV-GFP at MOIs of 100, 200, and 300 VP/cell for 2 hr on
U87MG, U251MG, GBM43, and GBM6, and the virus-containing medium was removed and replaced with fresh medium containing 2% FBS. After 72 hr, flow
cytometric analysis was performed. Each data point is the average of three independent replicates. Means– SEM are plotted.
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average infectivity of Ad5PK7-CMV-GFP was 63%
and that ofAd5GliomaFF-CMV-GFPwas70%on four
glioma cell lines. As such, Ad5GliomaFF-CMVGFP
exclusively infects glioma cells and does so with high
efficiency in a manner that can be applied safely for
glioma virotherapy (Fig. 2).
The kinetics of Ad5GliomaFF infectivity
Because the modified fibers were stably trimer-
ized and incorporated into this novel virus capsid
and showed highly specific infectivity on glioma
cells, we evaluated the kinetics of the viral infec-
tion to verify its infectivity efficiency in glioma
cells, using various multiplicities of infection (VP/
ml) on a panel of glioma cell lines. As the MOI of
Ad5GliomaFF increases, the infectivity of Ad5-
GliomaFF shows increased infectivity on glioma
cells (Fig. 3). Therefore, this novel virus has highly
stable kinetics of infectivity on these glioma cell
lines.
The efficient oncolytic activity
of Ad5GliomaFF-SurE1 in glioma cells
We have so far demonstrated that this novel
virus is highly stable (Figs. 1b and 3) and specifi-
cally infects glioma cellswith high efficiency (Fig. 2).
We sought to investigate the oncolytic activity of the
virus in glioma by replacing CMV-GFP (replication
incompetent) with Sur-E1 (conditionally replicating
under the survivin promoter). This transcriptional
regulation of viral replication under the control of
the survivin promoterwas thought to add evenmore
cancer-specific and safe viral characteristics for the
therapeutic use of this new virus. We first per-
formed crystal violet staining analysis on virus-
infected glioma and nonglioma cell lines (Fig. 4a).
Compared with Ad5WT, Ad5GliomaFF-SurE1
showed more efficient oncolytic activity on glioma
cell lines, at an MOI as low as 1VP/cell (Fig. 4a).
However, there was no observable reduction of
metabolic conversion rates and no cell-killing effects
on thenonglioma cell line, even at anMOI ashigh as
Figure 4. The efficient oncolytic activity of Ad5GliomaFF-SurE1. Cells were infected with Ad5GliomaFF-SurE1 or Ad5WT (a) at serially diluted MOI from 0 to
1000 VP/cell for 2 hr on U87MG, U251MG, GBM43, and GBM6 and the virus-containing medium was removed and replaced with fresh medium containing 2%
FBS. Eight days after viral infection, cells were fixed and stained with crystal violet. Micrographs were taken with a Nikon digital camera (d5100), followed by
dissolution with methanol, and read with a plate reader at OD570. Two of representative images are shown. (b) Cells were infected with Ad5GliomaFF-SurE1 or
Ad5WT at an MOI of 100 VP/cell for 2 hr on U87, U251, GBM43, and GBM6 and the virus-containing medium was removed and replaced with fresh medium
containing 2% FBS. At the time points of 24, 48, 72, and 96 hr, the MTT assay was performed according to the manufacturer’s instruction. Each data point and
column is the average of three independent replicates. Means– SEM are plotted. Color images available online at www.liebertpub.com/hum
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100VP/cell (Supplementary Fig. S2). To further
confirm the oncolytic activity of Ad5GliomaFF-
SurE1, we performed the MTT assay on two gli-
oma cell lines (U87 and U251: highly proliferating
cell lines in vitro) and two glioma cell lines ob-
tained from patient-derived xenografts (GBM43
and GBM6: minimally proliferating cell lines
in vitro) (Fig. 4b). Because the MTT assay is
based on the metabolic conversion of MTT to for-
mazan by the action of dehydrogenases, highly
proliferating cell lines show more dramatic chan-
ges of metabolic conversion. Whereas Ad5WT-
infected glioma cells showed a mere 10% reduc-
tion, Ad5GliomaFF-SurE1-infected glioma cells
showed a highly reduced metabolic conversion
rate, implying a high cell death rate. There was
a 75% reduction in highly proliferating glioma
cell lines and a 30–50% reduction in the patient-
derived xenograft glioma cell lines in 72–96hr (Fig.
4b). Therefore, this analysis indicates that Ad5-
GliomaFF-SurE1 is specifically oncolytic to glioma
cells but spares nonglioma cells from the lysing
effect.
Dynamics of viral replication
Because the efficacy of virotherapy depends
mainly on the viral replication-mediated oncolysis,
we next investigated the dynamics of viral repli-
cation in glioma cells by quantitative PCR. To
thoroughly analyze viral replication, we assessed
relative gene production of the replication-dictating
E1 (E1A and E1B), viral DNA replication-related
precursor terminal protein (pTP), and a structural
protein (fiber) from Ad5GliomaFF-SurE1-infected
cells compared with Ad5WT-infected cells.
First, the transcription from the E1 gene (E1A
andE1B) under the control of the survivin promoter
was significantly increased in Ad5GliomaFF-
SurE1-infected cells during the time period between
24 and 48hr compared with that with Ad5WT-
infected cells, implying efficient viral replication in
glioma (Fig. 5a and b). Also, a viral DNA replication-
related gene (precursor terminal protein, pTP) and
an adenovirus structural protein gene (fiber tail re-
gion) were analyzed. Again, the transcription from
both of these genes were significantly increased by
Ad5GliomaFF-SurE1-infected cells during the time
period between 24 and 48hr compared with that
by Ad5WT-infected cells, suggesting that efficient
growth of Ad5GliomaFF-SurE1 must be present in
the glioma cell lines and the patient-derived xeno-
graft glioma cell lines (Fig. 5c and d). Therefore,
Ad5GliomaFF-SurE1 can infect efficiently (Fig. 2)
and transcribe viral genes effectively in these
panels of glioma cell lines.
In vivo tumor growth suppression induced
by Ad5GliomaFF-SurE1
Collectively, the in vitro assays showed the
specificity and efficiency of Ad5GliomaFF-SurE1 in
the matter of targeting and oncolysis in glioma,
respectively. Hence, we next investigated tumor
progression/suppression in vivo by measuring the
bioluminescence of intracranially implanted U87-
Luc cells, using a xenograft murine model. Four
days after tumor implantation, mice were intra-
tumorally injectedwith either PBS or the virus (see
Materials and Methods for details). Noticeable in-
hibition of tumor growth was observed 5 days after
viral infection via the bioluminescence images
(p <0.05) and became readily apparent on day 10
after viral infection (p< 0.01) (Fig. 6a and b).
Therefore, the Ad5GliomaFF-SurE1-injected group
showed efficient suppression of tumor growth through
bioluminescence monitoring (Fig. 6).
The efficient oncolysis-based survival benefit
conferred by Ad5GliomaFF-SurE1
As Ad5GliomaFF-SurE1 efficiently suppressed the
growth of glioma, we sought to investigate further the
oncolysis-mediated survival effect of Ad5GliomaFF-
SurE1. In the same setting, we analyzed the survival
effect of Ad5GliomaFF-SurE1 with the U87-Luc-
implanted mouse model. As shown in Fig. 6a, the
median survival of the Ad5GliomaFF-SurE1-treated
groupwas extended by 50%comparedwith that of the
PBS-treated group; the median survival of the virus-
injected group was 61 days, which represented a
21-day increased median survival (p <0.05) over
the PBS-injected group (40 days) (Fig. 6c).
To further investigate the oncolytic efficiency of
Ad5GliomaFF-SurE1 in a more clinically relevant
model, we implanted the patient-derived glioma
xenograft cell line, GBM43, in the murine model.
As mentioned previously, the GBM43 cell line has
more intrinsic patient GBM properties and has
been propagated only in the flank of nude mice.18
Even with this highly aggressive and more intrinsic
patient-derived GBMmodel, we could see increased
median survival by 16 days whenmice were treated
with Ad5GliomaFF-Sur-E1; 70% extended median
survival as compared with the PBS-treated group
(p<0.001) (Fig. 6d). Therefore, this new virus is
highly specifically oncolytic to glioma and gives a
more than 50% extended life span to this virus-
treated group comparedwith the PBS-treated group.
DISCUSSION
Although various therapies have been devel-
oped to combat GBM, there has been little progress
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in the development of specific and more efficient
GBM-targeted therapeutic strategies without ad-
verse effects in a clinical context.1 In our studies,
the motive has been to develop a more specific, ef-
ficient, and safe virotherapeutic agent by incorpo-
rating the two imperative conditions of safety and
efficient oncolysis through viral genetic modifica-
tions on both structural and functional components
of the virus.
Because there is a lack of a targetable protein in
the heterogeneous glioma population, we selected
and incorporated phage panning-derived glioma-
specific peptides (VTW) on a fiber fibritin trimer-
ization domain that can stabilize the binding
moiety of targeting peptides. Together, these two
genetic modifications on the fiber domain eliminate
the natural tropism of adenovirus, provide CAR-
independent infection, and generate a new glioma-
specific tropism for the new adenoviral vector
(Ad5GliomaFF). Importantly, this new virus was
able to effectively differentiate glioma cells from
other cell types (both otherwise normal and
Figure 5. Dynamics of viral replication. Cells were infected with Ad5GliomaFF-SurE1 or Ad5WT at an MOI of 100 VP/cell for 2 hr on U87, U251, GBM43, and
GBM6. The virus-containing medium was removed and replaced with fresh medium containing 2% FBS. Both virus-infected cells and media were collected 24,
48, and 72 hr after viral infection and the DNA from each sample was isolated, followed by qPCR with primer sets for genes of the replication-dictating E1 (E1A
(a) and E1B (b)), viral DNA replication-related precursor terminal protein (pTP (c)), and a structural protein (fiber (d)). Each column represents the average
fold change in the respective gene of three independent replicates from Ad5GlimaFF-SurE1 compared with Ad5WT. Means–SEM are plotted.
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neoplastic at other anatomical sites). Of note, the
infection rate of cells of otherwise nonglioma dif-
ferentiation was almost undetectable (less than
1%) whereas about 70% of glioma cells were in-
fected with this virus.
In many cases, whenever a delivery vehicle is
designed to specifically target a certain cell popu-
lation, it is possible that it may lose its efficiency in
entering the target cells, because high specificity
often correlates with less efficiency. However, the
infectivity of the novel virus is highly comparable
to that of infectivity-enhanced Ad5PK7, which
suggests that the glioma-specific virus is not only
specific but also retains high efficiency for the in-
fection of glioma cells. With highly stable kinetics
of infection in addition to its highly specific and
efficient infection capability, the glioma-specific
virus is capable of efficient oncolysis even at a low
MOI. Of note, this oncolysis was possibly due to the
efficient viral replication in glioma as the produc-
tion of viral genes: replication-dictating gene (E1),
viral DNA replication-related gene (pTP), struc-
tural protein-producing gene (fiber) was signifi-
cantly increased between 24 and 48hr compared
with Ad5WT, which further implies the high po-
tential of the new virus for clinical therapeutic
use because the clinical therapeutic efficacy de-
pends mostly on viral replication-mediated onco-
lysis.3,23,24 Mechanistically, this virus specifically
recognizes and infects glioma cells, replicates expo-
nentially between 24 and 48hr, and efficiently lyses
glioma cells in 72hr. Further, tumor progression/
suppression and survival analysis in vivo showed
efficient suppression of tumor growth, which
gives the extended median survival of the Ad5-
GliomaFF-SurE1-treated group.
The efficacy of adenovirus-mediated therapeutic
applications in the clinic has been shown to be
Figure 6. In vivo tumor growth suppression and the survival benefit conferred by Ad5GliomaFF-SurE1. Mice bearing intracranial U87-Luc tumors were treated
with PBS or Ad5GliomaFF-SurE1. (a) Bioluminescence was measured 3, 10, and 30 days after tumor implantation and images were acquired at each time point.
(b) Bioluminescence was plotted as average radiance versus days after tumor implantation. Coloration indicates pixel intensity of bioluminescence, which is
related to the number of tumor cells. Each data point is the average of four mice (PBS-treated group) or that of five mice (Ad5GliomaFF-SurE1-treated group).
Means and SE are plotted. For the survival analysis, mice bearing intracranial U87-Luc (c) or patient-derived xenograft GBM43 (d) tumors were treated with
PBS or Ad5GliomaFF-SurE1 (see Materials and Methods for details). The Kaplan–Meier survival curves of treated mice were analyzed. *p < 0.05, **p < 0.01, and
***p < 0.001. Color images available online at www.liebertpub.com/hum
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minimal because most people have already been
exposed to HAd5, and have generated neutralizing
antibodies against the adenovirus.25,26 Also, in the
matter of systemic delivery, HAd5 has been shown
to have liver tropism, resulting in liver toxicity.25
However, because the majority of these neutral-
izing antibodies recognize either hexon (the most
abundant viral protein) or fiber (the most pro-
truded protein),26 these two domains can be easily
modified to prevent antiviral responses.25,27 In
our research, we replaced the wild-type fiber
with the T4 phage-oriented trimer structure, to
which neutralizing antibodies are highly unlikely
to be present in humans, to minimize antiviral re-
sponses against the fiber antigen. Of note, we did
not explore the hexon-modified approach to mini-
mize the liver toxicity and the effect of antiviral
neutralizing antibodies. This is becausewe injected
the virus intratumorally into the brain and ade-
novirus cannot pass the brain–blood barrier (BBB)
because of the permissive size limitation.28 Be-
cause the hexon can be targeted for antiviral re-
sponses, we can, in future research, modify the
hexon to further maximize the virotherapeutic
efficacy.
It was reported that virotherapeutic approaches
can be augmented when virus-mediated onco-
lysis can induce further immune responses against
tumor.29–31 In this regard, approaches that can
efficiently kill tumor cells, almost to the extent of
bombarding the tumor areawith an oncolytic virus,
were emphasized in the hope that they could in-
duce a stronger, more potent antitumor immune
response. However, these efficiency-oriented ap-
proaches, as previously said, sometimes caused the
death of normal bystander cells, which also can
induce unwanted immune responses against non-
tumor-derived self-antigen(s). Consequentially, for
more advanced and optimized virotherapy, effi-
cacy must be achieved along with the specificity
that our new, advanced approach has shown. To
further enhance the antitumor immune response,
synergizing with efficient oncolytic activity, we
can also deliver immune modulator(s) such as
PD-L1 and anti-CTLA432 on this optimized glioma-
targeted virus.
In summary, we have presented here the mul-
tilevel genetic modification of a highly specific
and efficient glioma-targeted virus that exponen-
tially replicates and induces oncolysis specifically
within malignant glioma cells. We showed that
therapeutic treatment with this virus efficiently
suppressed the growth of glioma and substantially
extended median survival. We strongly believe
that this approach represents a strong platform
for future virotherapy, is highly translational,
and could achieve promising therapeutic results in
human clinical applications.
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